jetcityimage/iStock Editorial via Getty Images
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), on Friday declined to endorse Kisunla (donanemab), Eli Lilly’s (NYSE:LLY) candidate for early Alzheimer’s disease, citing concerns over its risk-benefit profile.
The FDA approved the amyloid-targeting therapy
